A novel association of CCDC80 with gestational diabetes mellitus in pregnant women: a propensity score analysis from a case-control study

Abstract

Background: Gestational diabetes mellitus (GDM) is a growing global epidemic. Our study aims to confirm the association between circulatory coiled-coil domain-containing 80 (CCDC80) in pregnant women with GDM, to investigate the discriminatory power of CCDC80 on GDM, and to explore the relationships between this molecular level and clinical cardiometabolic parameters. Methods: A 1:2 matched case-control study with 61 GDM patients and 122 controls was conducted using a propensity score matching protocol. All participants were screened from a multicenter prospective pre-birth cohort: Born in Shenyang Cohort Study (BISCS). During 24 and 28 weeks of gestation, follow-up individuals underwent an oral glucose tolerance test (OGTT) and blood sampling for cardiometabolic characterization. Results: Following propensity score matching adjustment for clinical variables, including maternal age, gestational age, body mass index, SBP and DBP, plasma CCDC80 levels were significantly decreased in patients with GDM when compared with controls (0.25 ± 0.10 vs. 0.31 ± 0.12 ng/ml, P = 0.003). Conditional multi-logistic regression analyses after adjustments for potential confounding factors revealed that CCDC80 was a strong and independent protective factor for GDM (ORs < 1). In addition, the results of the ROC analysis indicated the CCDC80 exhibited the capability to identify pregnant women with GDM (AUC = 0.633). Finally, multivariate regression analyses showed that CCDC80 levels were positively associated with AST, monoamine oxidase, complement C1q, LDL-C, apolipoprotein A1and B, and negatively associated with blood glucose levels at 1 h post-OGTT. Conclusions: Biomarker CCDC80 could be of great value for the development of prediction, diagnosis and therapeutic strategies against GDM in pregnant women.

Obesity promotes pancreatic cancer through the ECM-PI3K-AKT signaling axis

“…In a paired study of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), it was rst found to be associated with altered VAT obesity secretion fractions and disturbed glucose tolerance and was de ned as an adipokine [20]. In another study, it was also mentioned that CCDC80 may be involved in energy and insulin metabolism in vivo, which is of great value for the prediction, diagnosis, and treatment strategy selection of gestational diabetes [21], and it was also mentioned that CCDC80 de ciency increases plasma and liver cholesterol levels in mice, leading to a greater susceptibility to hypercholesterolemia [22] and that the adipokine CCDC80 could be a predictive target for atherosclerosis in patients with in ammatory bowel disease [23]. In addition, the knockdown of CCDC80 in mouse models was found to reduce PPAR signaling processes and fatty acid degradation, leading to decreased levels of arachidonic and -linolenic acid metabolism [24]and promoting fat accumulation.…”